Time trends in the risk of delayed cerebral ischemia after subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.

aneurysmal subarachnoid hemorrhage cerebral vasospasm delayed cerebral ischemia delayed ischemic neurologic deficit meta-analysis

Journal

Neurosurgical focus
ISSN: 1092-0684
Titre abrégé: Neurosurg Focus
Pays: United States
ID NLM: 100896471

Informations de publication

Date de publication:
03 2022
Historique:
received: 08 08 2021
accepted: 21 12 2021
entrez: 1 3 2022
pubmed: 2 3 2022
medline: 7 4 2022
Statut: ppublish

Résumé

Delayed cerebral ischemia (DCI) contributes to morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). Continuous improvement in the management of these patients, such as neurocritical care and aneurysm repair, may decrease the prevalence of DCI. In this study, the authors aimed to investigate potential time trends in the prevalence of DCI in clinical studies of DCI within the last 20 years. PubMed, Embase, and the Cochrane library were searched from 2000 to 2020. Randomized controlled trials that reported clinical (and radiological) DCI in patients with aSAH who were randomized to a control group receiving standard care were included. DCI prevalence was estimated by means of random-effects meta-analysis, and subgroup analyses were performed for the DCI sum score, Fisher grade, clinical grade on admission, and aneurysm treatment method. Time trends were evaluated by meta-regression. The search strategy yielded 5931 records, of which 58 randomized controlled trials were included. A total of 4424 patients in the control arm were included. The overall prevalence of DCI was 0.29 (95% CI 0.26-0.32). The event rate for prevalence of DCI among the high-quality studies was 0.30 (95% CI 0.25-0.34) and did not decrease over time (0.25% decline per year; 95% CI -2.49% to 1.99%, p = 0.819). DCI prevalence was higher in studies that included only higher clinical or Fisher grades, and in studies that included only clipping as the treatment modality. Overall DCI prevalence in patients with aSAH was 0.29 (95% CI 0.26-0.32) and did not decrease over time in the control groups of the included randomized controlled trials.

Identifiants

pubmed: 35231892
doi: 10.3171/2021.12.FOCUS21473
pii: 2021.12.FOCUS21473
doi:
pii:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

E2

Auteurs

Luigi Rigante (L)

1Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.

Jasper Hans van Lieshout (JH)

2Department of Neurosurgery, Henrich-Heine-University Düsseldorf, Germany.

Mervyn D I Vergouwen (MDI)

3Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.

Carlijn H S van Griensven (CHS)

4Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.

Priya Vart (P)

5Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands.

Lars van der Loo (L)

6Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.

Joost de Vries (J)

1Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.

Ruben Saman Vinke (RS)

1Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.

Nima Etminan (N)

7Department of Neurosurgery, Universitätsmedizin Mannheim, Germany.

Rene Aquarius (R)

1Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.

Andreas Gruber (A)

8Department of Neurosurgery, Kepler University Hospital, Linz, Austria.

J Mocco (J)

9Department of Neurosurgery, Mount Sinai Health System, New York, New York.

Babu G Welch (BG)

10Department of Neurosurgery, University of Texas Southwestern, Dallas, Texas.

Tomas Menovsky (T)

11Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.

Catharina J M Klijn (CJM)

12Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands; and.

Ronald H M A Bartels (RHMA)

1Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.

Menno R Germans (MR)

13Department of Neurosurgery, University Hospital Zurich and Clinical Neuroscience Center, Zurich, Switzerland.

Daniel Hänggi (D)

2Department of Neurosurgery, Henrich-Heine-University Düsseldorf, Germany.

Hieronymus D Boogaarts (HD)

1Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH